Bend but Don’t Break? A Case of Supera Stent Fracture in the Popliteal Artery

Valle JA, Famouri A and Rogers RK

University of Colorado, Aurora, CO, USA

Corresponding author: R Kevin Rogers
kevin.rogers@ucdenver.edu

Program Director/Vascular Medicine and Intervention, Interventional Cardiology, University of Colorado, Mail Stop B132, Leprino Building, 12401 East 17th Avenue, Room 560, Aurora, CO 80045, USA.
Tel: 720848-6506
Fax: 720848-7315


Introduction

Peripheral arterial stent fracture is a known complication of peripheral intervention and is associated with increased risk of in-stent restenosis and re-occlusion of the target vessel [1,2]. While reported rates of stent fracture have varied widely overall [1], stent location has been implicated as a risk factor for fracture. Stent deployment in one such location, the femoropopliteal segment, has been associated with elevated rates of stent fracture [2]. The Supera peripheral stent (Abbott Vascular, Tamecula) has a novel, interwoven nitinol platform that was designed to have longitudinal and axial flexibility to specifically withstand the torsional and compressive forces encountered in the femoropopliteal anatomy. With 1,100 reported implantations across 7 registries, there have been no reported fractures at 1 year follow-up [3]. Thus, the Supera remains the only peripheral stent indicated for popliteal arterial lesions, due to its ability to withstand the torsion behind the knee. However, the data supporting its use is observational alone, with the majority only completing 1 year of follow-up [3]. In this case, we describe the first report of a Supera peripheral stent fracture.

Case Report

The patient is a 59 year-old male with lifestyle-limiting right calf claudication and ischemic rest pain (Rutherford category 3-4), who initially presented for evaluation after non-invasive studies had suggested the presence of a right popliteal occlusion. He underwent a complex intervention involving antegrade and retrograde attempts at recanalization, complicated by dissection preventing further attempts. A Vascular Surgery consultation was requested, but it was thought the patient did not have adequate conduits to support a surgical intervention for symptom relief. Following 3 months of ongoing medical optimization and a walking program, the patient returned for a peripheral angiography, and a repeat attempt at recanalization of the popliteal occlusion. After retrograde crossing of the lesion, orbital atherectomy was performed followed by pre-dilation with a 4.0 x 100 mm angioplasty balloon at high pressure (Figure 1). A 4.0 x 100 mm Supera self-expanding stent was then deployed across the popliteal lesion with particular care to avoid excessive elongation (Figure 2). Final angiography demonstrated a patent, well expanded stent in the right popliteal artery, and intact tibioperoneal vessels distally, without any evidence of dissection, distal embolization, or perforation (Figure 3).

Three months later, the patient returned to Peripheral Vascular Clinic with recurrence of ischemic symptoms involving his right calf and foot. His symptoms had initially been improved for approximately 2 months immediately after popliteal stenting. Over the following month, the patient had had worsening right lower extremity symptoms, with foot and calf discomfort on any kind of ambulation. Non-invasive studies with duplex...
ultrasonography demonstrated significant velocity increases across the distal superficial femoral artery and proximal popliteal artery, suggestive of high grade stenosis within the proximal stent.

The patient underwent a repeat diagnostic angiography, which demonstrated fracture of the previously placed Supera stent, with complete non-union of stent struts in the mid stent (Figures 4a and 4b), and a long segment of severe (80%) in-stent restenosis proximal and distal to the fracture. Subsequent angioplasty was performed across the stent fracture with a scoring balloon. Given the prior fracture, the decision was made to avoid repeat stenting.

**Discussion**

This case represents the first report of a Supera stent fracture in the literature. While the unique design of Supera may decrease the incidence of stent fracture, there are no randomized trials comparing Supera to traditional stents to support this claim.
Moreover, the registry data has been limited in long-term follow-up. Technological advances like the Supera are needed to optimize outcomes for the endovascular treatment of femoropopliteal disease, but further investigation and longer term follow-up are needed to fully evaluate these novel designs and their efficacy.

**Conclusion**

The Supera stent platform is a promising modality for the endovascular treatment of femoropopliteal peripheral vascular disease; however further investigation and longer-term follow-up are needed to ensure efficacy.
References

